Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-resistant Fallopian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT01202890
What this trial is testing

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Carcinoma+1 more
New Mexico Cancer Research Alliance 1
Testing effectiveness (Phase 2)UnknownNCT03188159
What this trial is testing

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube Cancer
National University Hospital, Singapore 36
Testing effectiveness (Phase 2)Study completedNCT02272790
What this trial is testing

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
AstraZeneca 95
Testing effectiveness (Phase 2)Looking for participantsNCT06682988
What this trial is testing

Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Who this might be right for
Advanced High-Grade Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancers
AbbVie 110
Large-scale testing (Phase 3)Active Not RecruitingNCT02839707
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous AdenocarcinomaOvarian Seromucinous Carcinoma+16 more
National Cancer Institute (NCI) 444
Testing effectiveness (Phase 2)Ended earlyNCT03311334
What this trial is testing

DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Urothelial CarcinomaPrimary Peritoneal Cancer+3 more
Sumitomo Pharma America, Inc. 47
Testing effectiveness (Phase 2)UnknownNCT04376073
What this trial is testing

Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Jihong Liu 40
Testing effectiveness (Phase 2)Study completedNCT00301756
What this trial is testing

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors

Who this might be right for
Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Borderline Ovarian Surface Epithelial-Stromal Tumor+5 more
National Cancer Institute (NCI) 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595892
What this trial is testing

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Ovarian Serous TumorRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 70
Large-scale testing (Phase 3)Study completedNCT00191607
What this trial is testing

Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Who this might be right for
Genital Neoplasms, FemaleFallopian Tube NeoplasmsOvarian Neoplasms+2 more
Eli Lilly and Company 162
Testing effectiveness (Phase 2)Study completedNCT02312245
What this trial is testing

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Mayo Clinic 13
Testing effectiveness (Phase 2)Looking for participantsNCT06434610
What this trial is testing

B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
Shanghai Jiaolian Drug Research and Development Co., Ltd 90
Testing effectiveness (Phase 2)Study completedNCT02659384
What this trial is testing

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
European Organisation for Research and Treatment of Cancer - EORTC 122
Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230
Large-scale testing (Phase 3)UnknownNCT05622890
What this trial is testing

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT05271318
What this trial is testing

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Who this might be right for
Platinum-refractory Ovarian CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube Carcinoma+6 more
TILT Biotherapeutics Ltd. 29
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Testing effectiveness (Phase 2)UnknownNCT02188550
What this trial is testing

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Who this might be right for
Ovarian CancerEndometrial Cancer
Sinai Hospital of Baltimore 20
Early research (Phase 1)Study completedNCT00059618
What this trial is testing

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
M.D. Anderson Cancer Center 21
Large-scale testing (Phase 3)Study completedNCT04209855
What this trial is testing

Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Who this might be right for
Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer
AbbVie 453
Next Page